Moderna Works on Vaccines to Get Ahead of Covid-19 Variants

The transcript discusses the efficacy of vaccines against COVID-19, including the potential need for revaccination due to variants. It highlights Moderna's trials for children and the biotech industry's role in developing treatments. The speaker also talks about Flagship Pioneering's innovative approach to creating biotech companies and the importance of leadership in driving these initiatives.

What is the current evidence regarding the duration of antibody protection after full vaccination?

• At least six months

• At least two years

• At least one year

• At least three months

What is Moderna's approach to dealing with virus variants?

• Using traditional vaccines

• Increasing the dosage of existing vaccines

• Developing additional mRNA vaccines

• Stopping vaccine production

What age group is Moderna currently testing their vaccine on?

• 18 to 25 years

• Newborns to 6 months

• 6 months to 12 years

• 12 to 18 years

What is the expected timeline for sharing data from the vaccine trials on children?

• In a few weeks

• Over the coming months

• In a few days

• In a year

What is Kaleido working on in relation to COVID-19?

• A new vaccine

• An oral treatment

• A surgical procedure

• A diagnostic test

What is the main focus of Flagship Pioneering?

• Inventing and launching new biotech companies

• Manufacturing medical equipment

• Providing healthcare services

• Developing new vaccines

What is a key factor in the success of Flagship Pioneering's companies?

• Large marketing campaigns

• Government funding

• Forming a strong leadership team

• High product prices